

REMARKS

Claims 1, 15, 19-20, 26, 29-30, 72 and 136 have been canceled without prejudice or disclaimer. Claims 73-81, 88-89, 91, 137-145, 152-153, and 155, as presented in Paper No. 6, filed June 23, 2003, did not refer to the appropriate independent claim. Thus, claims 73-81, 88-89, 91, 137-145, 152-153, and 155 have been amended to make reference to the appropriate independent claim. New claim 162, which is very similar to allowed claim 98, was added to further claim an embodiment of Applicants' invention. Claim 162, directed to a method of detection with an Fab fragment, is fully supported by the specification, for example, on page 44, penultimate paragraph. Thus, no new matter has been added.

Claims 35-71, 73-135, and 137-162 will be pending upon entry of these amendments. Claims 35-161 were previously allowed.

Information Disclosure Statement

In the office action of August 20, 2003, Paper No. 7, the Examiner states the following:

In the PTO-1449 submitted [November 6, 2001], the last two references have been lined out. Parts of what could possibly be U.S. Patent applications have been submitted but there is absolutely no identification as to what applications these are.

Applicants have resubmitted copies of the last two references of form PTO-1449/SB/08, AU and AV. To clarify the identities of the submitted documents, each has been labeled in the upper right hand corner with their citation number, and an identifying sticker has also been placed on the back side of each reference. Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Double Patenting Rejection

Rejection of claims 1, 15, and 20 under the judicially created doctrine of obviousness-type double patenting is moot as claims 1, 15, and 20 have been canceled.


CONCLUSION

Applicants respectfully request that the above-made remarks be entered and made of record in the file history of the instant application. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the examination of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: 11-20-03



Lin J. Hymel (Reg. No. 45,414)
Patent Attorney

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(240) 314-4400 ext. 3595

MMW/LJH/DAS/ZSS